Thromb Haemost 2002; 87(02): 356-358
DOI: 10.1055/s-0037-1613007
Letters to the Editor
Schattauer GmbH

Thrombosis-associated Gene Variants in Sickle Cell Anemia

M. Romana
1   INSERM U 458, Hôpital Robert Debré, Paris, France
,
S. Muralitharan
1   INSERM U 458, Hôpital Robert Debré, Paris, France
,
R. Ramasawmy
1   INSERM U 458, Hôpital Robert Debré, Paris, France
,
L.R. Nagel
2   Dept. of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA
,
R. Krishnamoorthy
1   INSERM U 458, Hôpital Robert Debré, Paris, France
› Author Affiliations
Further Information

Publication History

Received 16 January 2001

Accepted after resubmission 24 September 2001

Publication Date:
13 December 2017 (online)

 

 
  • References

  • 1 Serjeant GR. Sickle cell disease. Lancet 1997; 350: 725-32.
  • 2 Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997; 337: 762-9.
  • 3 Browne PV, Mosher DF, Steinberg MH, Hebbel RP. Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. Am J Hematol 1996; 51: 296-301.
  • 4 Francis RB, Johnson CS. Vascular occlusion in sickle cell disease: current concepts and unanswered questions. Blood 1991; 77: 1405-14.
  • 5 Aldrich TK, Dhupper SK, Patwa NS, Makalo E, Suzuka SM, Najeebi SA. Santhanakrishnan S, Nagel RL, Fabry ME. Pulmonary entrapment of sickle cells: the role of regional alveolar hypoxia. J Appl Physiol 1996; 531-9.
  • 6 Billett HH, Nagel RL, Fabry ME. Evolution of laboratory parameters during sickle cell painful crisis: evidence with dense cell sequestration without thrombosis. Am J Med Sci 1988; 31: 293-8.
  • 7 Liesner R, Mackie I, Cookson J, McDonald S, Chitolie A, Donohoe S. Evans J, Hann I, Machin S Prothrombotic changes in children with sickle cell disease: relationships to cerebrovascular disease and transfusion. Br J Haematol 1998; 103: 1037-44.
  • 8 Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variant in the 3’ - untranslated region of the prothrombin gene is associated with elevated plasma protoombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-702.
  • 9 Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Mattheusy RG, Boers GHJ, den Heijer M, Kluijtmans LAJ, van clen Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-3.
  • 10 Tsai MY, Bignell M, Schwichtenberg K, Hanson NQ. High prevalence of a mutation in the cystathionine b synthase gene. Am J Hum Genet 1996; 59: 1262-7.
  • 11 Reiner AP, Siscovick DS, Rosendall FR. Hemostatic risk factors and arterial thrombotic disease. Thromb Haemost 2001; 85: 584-95.
  • 12 Gill FM, Sleeper LA, Weiner SJ, Brown AK, Bellevue R, Grover R. Pegelow CH, Vichinsky E Clinical events in the first decade in a cohort of infants with sickle cell disease. Blood 1995; 86: 776-83.
  • 13 Mukisi-Mukaza M, Elbaz A, Samuel-Leborgne Y, Kéclard L, Le Turdu-Chicot C, Christophe-Duchange E, Merault G. Prevalence clinical features and risk factors of osteonecrosis of the femoral head among adults with sickle cell disease. Orthopedics 2000; 23: 357-63.
  • 14 D’Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997; 90: 1-11.
  • 15 Sperandera MP, de Franchs R, Andria G, Sebastio G. A 68 bp insertion found in a homocystinuric patient is a common variant and is skipped by alternative splicing of the cystathionine b-synthase mRNA. Am J Hum Genet 1996; 59: 1391-3.